Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
about
Huntingtin is critical both pre- and postsynaptically for long-term learning-related synaptic plasticity in AplysiaThe importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseDisruption of axonal transport perturbs bone morphogenetic protein (BMP)--signaling and contributes to synaptic abnormalities in two neurodegenerative diseasesRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesAn ovine transgenic Huntington's disease model.Abnormal motor cortex plasticity in premanifest and very early manifest Huntington diseaseSelective roles of normal and mutant huntingtin in neural induction and early neurogenesisDifferential Changes in Postsynaptic Density Proteins in Postmortem Huntington's Disease and Parkinson's Disease Human Brains.Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathwayThe sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington diseaseMonitoring Huntington's disease progression through preclinical and early stagesTranscranial magnetic stimulation: from neurophysiology to pharmacology, molecular biology and genomics.Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques.Biomarkers for Huntington's disease: an update.Neurophysiology in Huntington's disease: an update.Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases.Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells.Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease.Hyperkinetic disorders and loss of synaptic downscaling.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease.Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.Brain stimulation in Huntington's disease.Changes in motor cortical excitability in patients with Sydenham's chorea.Assessing the functional status of the motor system in brain tumor patients using transcranial magnetic stimulation.Evaluation of Cognition and Cortical Excitability in Huntington's Disease.
P2860
Q21131986-5BFF8E96-EB54-4A20-97E2-1468B646D4D6Q22306292-A1B75112-7405-406B-86C1-08AD4701A5C0Q27315692-4E324ECE-B107-4FE2-BB12-D2E8408A2697Q28072353-76CC920D-BD5C-41CA-B7BF-25AABD00D00AQ33815561-59F2B59F-0FE9-4C41-ADB2-B756921AECFFQ34382326-EE6BE329-7B9E-4295-9E8F-1E40D5881AD0Q34731481-139D9577-2329-47F8-9410-F4117832C7A6Q35623502-332F0B3B-C57E-403C-8D15-AC5BFD75FD94Q36090810-22591437-7088-4E27-BBC8-1798139C4DD3Q36183832-40BA562F-DE2E-40B2-B0C5-2FC33963E292Q36459201-18E46292-0D98-47D2-8FBB-57B54F53646EQ37681913-49D374DD-BFD5-40A8-B3B4-358B85E0B9B6Q38028376-E779E657-FDEC-42D0-BB75-24FB64DC508EQ38088407-E9E4D122-0ECF-4006-85FF-41EA25956B47Q38212035-EA3DEF0D-3013-43EB-83C4-18F15B38B613Q38636878-B4D9A2C8-EF9E-4C2E-B247-E7BF6FC8BF36Q38790183-284170B1-308A-48AD-8335-46490606A8CEQ38796845-6BE924A2-80E1-4413-840E-916F68F3B564Q38847727-B082CFA5-1CFF-4B83-83AB-873ABD2990C6Q38928777-B3A47E7B-CB39-425C-9AD1-480B3AA59D13Q40295370-71C88370-5CFF-4745-8384-AF3B02AC5F8FQ42098044-3DD0639D-9DBF-499D-8B36-C4D935A9816BQ44832011-D04438DD-F0AA-434A-8F28-6A173DEF2B96Q45289548-0DC4CEDB-891E-4673-993A-7532F1526D74Q45295397-90483428-7302-4433-8056-D091E3C2FAB6Q45299652-62549F5C-14CF-4A5D-9060-DBAB0C529C15Q47188711-A7E40621-EFFA-42D4-BE39-6CB3F89138A0Q47558279-7441A7F2-6DC6-46FA-96D0-7DD02104EB51
P2860
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@ast
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@en
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@nl
type
label
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@ast
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@en
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@nl
prefLabel
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@ast
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@en
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@nl
P2093
P2860
P50
P1476
Abnormal motor cortex excitability in preclinical and very early Huntington's disease.
@en
P2093
Khailash P Bhatia
Susanne A Schneider
Sven Schippling
P2860
P304
P356
10.1016/J.BIOPSYCH.2008.12.026
P407
P577
2009-02-07T00:00:00Z